APA (7th ed.) Citation

T, K., Y, T., T, T., K, T., K, Y., J, M., . . . H, K. (2025). Bridging in vitro and clinical data: Experimental insights into the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor. Drug metabolism and disposition: the biological fate of chemicals, 53(6), 100087. https://doi.org/10.1016/j.dmd.2025.100087

Chicago Style (17th ed.) Citation

T, Koishikawa, et al. "Bridging in Vitro and Clinical Data: Experimental Insights into the IC50 Variability of Dolutegravir as an Organic Cation Transporter 2 Inhibitor." Drug Metabolism and Disposition: The Biological Fate of Chemicals 53, no. 6 (2025): 100087. https://doi.org/10.1016/j.dmd.2025.100087.

MLA (9th ed.) Citation

T, Koishikawa, et al. "Bridging in Vitro and Clinical Data: Experimental Insights into the IC50 Variability of Dolutegravir as an Organic Cation Transporter 2 Inhibitor." Drug Metabolism and Disposition: The Biological Fate of Chemicals, vol. 53, no. 6, 2025, p. 100087, https://doi.org/10.1016/j.dmd.2025.100087.